LONDON, October 28, 2014 /PRNewswire/ --
New report from Globe Life Sciences finds that combination therapy may be the key that finally allows cancer vaccines to fulfil their potential
Globe Life Sciences, a leading provider of commercial analysis within healthcare-related sectors, conducted a detailed review of 17 late-stage cancer vaccines. The Globe Extraordinary report, entitled 'Future of Cancer Vaccines - An Analysis of Late-stage Products', concludes - after a history of failures - combination therapy may be the key that finally allows cancer vaccines to fulfil their potential.
Cancer vaccines have long been on the horizon as a potential major new treatment paradigm, but the field has been littered with technical failures. Over the past 18 months, there have been yet more disappointments, as several high profile Phase III trials have not met their primary endpoints. The field is now entering a critical period as results are pending from further pivotal trials that could have an important role in shaping the future direction of cancer vaccines.
This report provides an in-depth, qualitative assessment of 17 cancer vaccines in late-stage development based on detailed desk research and insight from 15 opinion-leading clinicians. It individually assesses the potential of each vaccine, identifies key risks and commercialisation issues and determines whether cancer vaccines could experience the same level of success as the immune checkpoint inhibitors in the near-term future. Overall, the report uncovers the likely future directions in the cancer vaccine field and the potential challenges facing this move.
For further information or to purchase this report, please contact sales:
About Globe Life Sciences and Globe Extraordinary
Globe Life Sciences provides commercial evaluation and information services within healthcare-related sectors.
Globe Life Sciences also provides off the shelf reports and databases to its healthcare clients under the Globe Extraordinary label. Globe Extraordinary reports are intended to assist managers in shaping and structuring their thinking in strategy development. Unlike our commercial evaluation service, these reports are designed for general - and often introductory - use.
CONTACT: Amy Versey +44 (0) 208 334 7070